Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Epizyme stock

Learn how to easily invest in Epizyme stock.

About 21 hours ago


+$0.06 (+0.78%)

Epizyme is a biotechnology business based in the US. Epizyme shares (EPZM) are listed on the NASDAQ and all prices are listed in US Dollars. Epizyme employs 250 staff and has a trailing 12-month revenue of around $53 million.

How to buy Epizyme stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – EPZM. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for social trading

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for active trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Epizyme stock price (NASDAQ: EPZM)

Use our graph to track the performance of EPZM stocks over time.

Epizyme shares at a glance

Information last updated 2022-11-06.
Latest market close$1.47
52-week range$0.00 - $0.00
50-day moving average $1.25
200-day moving average $1.67
Wall St. target price$6.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.09

Buy Epizyme stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Ratings Available asset types Minimum deposit Signup bonus
SoFi Invest
Finder Rating: 4.6 / 5: ★★★★★

Finder Award
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Rating: 4.2 / 5: ★★★★★

Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Finder Rating: 4.1 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
2.5% fee applies to all alternative asset transactions.
Finder Rating: 4.2 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4.9% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Finder Rating: 4 / 5: ★★★★★
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $5,000 - $250,000+
Pay no commissions on stocks, ETFs, mutual funds and options.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs
Wealthfront builds a free financial plan for the life you want and automate your investments at a low cost.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Epizyme stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Epizyme price performance over time

Historical closes compared with the close of $1.47 from 2022-08-12

1 week (2023-09-12) N/A
1 month (2023-08-19) N/A
3 months (2023-06-19) N/A
6 months (2023-03-19) N/A
1 year (2022-09-19) N/A
2 years (2021-09-23) -73.13%
3 years (2020-09-23) 11.94
5 years (2018-09-21) 10.25

Epizyme financials

Revenue TTM $53 million
Gross profit TTM $18.6 million
Return on assets TTM -39.25%
Return on equity TTM -877.48%
Profit margin 0%
Book value $0.85
Market Capitalization $247.5 million

TTM: trailing 12 months

Epizyme share dividends

We're not expecting Epizyme to pay a dividend over the next 12 months.

Epizyme share price volatility

Over the last 12 months, Epizyme's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Epizyme's is -0.4181. This would suggest that Epizyme's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Epizyme has bucked the trend.

Epizyme overview

Epizyme, Inc. , a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc. ; Lymphoma Academic Research Organization; Eisai Co.

Frequently asked questions

What percentage of Epizyme is owned by insiders or institutions?
Currently 0.584% of Epizyme shares are held by insiders and 81.047% by institutions.
How many people work for Epizyme?
Latest data suggests 250 work at Epizyme.
When does the fiscal year end for Epizyme?
Epizyme's fiscal year ends in December.
Where is Epizyme based?
Epizyme's address is: 400 Technology Square, Cambridge, MA, United States, 02139
What is Epizyme's ISIN number?
Epizyme's international securities identification number is: US29428V1044
What is Epizyme's CUSIP number?
Epizyme's Committee on Uniform Securities Identification Procedures number is: 29428V104

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site